BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30605381)

  • 1. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
    Marquardt TM; Lindley SES; Smith AN; Cannon CM; Rodriguez CO; Thamm DH; Childress MO; Northrup NC
    J Am Vet Med Assoc; 2019 Jan; 254(2):236-242. PubMed ID: 30605381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
    Wang SL; Lee JJ; Liao AT
    Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
    Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
    Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a multiagent chemotherapy protocol combining vincristine, cyclophosphamide, mitoxantrone and prednisolone (CMOP) for treatment of feline intermediate-large cell lymphoma.
    Webster J; McNaught KA; Morris JS
    J Feline Med Surg; 2024 Apr; 26(4):1098612X241234614. PubMed ID: 38647264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
    Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
    Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
    Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
    J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol.
    Veluvolu S; Pellin M; Vos N
    J Am Vet Med Assoc; 2021 Sep; 259(5):494-502. PubMed ID: 34388019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
    Burton JH; Garrett-Mayer E; Thamm DH
    Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol.
    Tomiyasu H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2010 Nov; 72(11):1391-7. PubMed ID: 20543531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
    Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
    Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
    Curran K; Thamm DH
    Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol.
    Wilson-Robles H; Budke CM; Miller T; Dervisis N; Novosad A; Wright Z; Thamm DH; Vickery K; Burgess K; Childress M; Lori J; Saba C; Rau S; Silver M; Post G; Reeds K; Gillings S; Schleis S; Stein T; Brugmann B; DeRegis C; Smrkovski O; Lawrence J; Laver T
    Vet Comp Oncol; 2017 Dec; 15(4):1564-1571. PubMed ID: 28419683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
    Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
    J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
    Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
    J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
    Rassnick KM; Bailey DB; Malone EK; Intile JL; Kiselow MA; Flory AB; Barlow LL; Balkman CE; Barnard SM; Waite AH
    Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
    Pangalis GA; Vassilakopoulos TP; Michalis E; Roussou P; Vrakidou E; Repousis P; Angelopoulou MK; Siakantaris MP; Korantzis J; Symeonidis A; Grigorakis V; Stefanoudakis E; Stamatellou M; Bourantas KL; Kalmantis T; Christopoulos G; Kokkinis G; Mihalakeas I; Papayiannis A;
    Leuk Lymphoma; 2003 Apr; 44(4):635-44. PubMed ID: 12769340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.
    Benjamin SE; Sorenmo KU; Krick EL; Salah P; Walsh KA; Weinstein NM; Keuler NS; Avery AC; Atherton MJ; Lenz JA
    Vet Comp Oncol; 2021 Sep; 19(3):541-550. PubMed ID: 33729654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.